Developer docs
API playgroundTry for free, no card

Search company profiles

Citi Pharma

Full company profile

uuid006e89h

Namestring
Citi Pharma
Legal namestring
Citi Pharma Limited
Company typeenum
Public
Founded yearint
1993
Descriptiontext

Citi Pharma Limited is a Pakistan-based pharmaceutical company founded in 1992 and headquartered in Lahore, operating as a publicly listed entity on the Pakistan Stock Exchange with offices in Lahore and Karachi and a manufacturing facility in Bhai Pheru, District Kasur. The company operates a three-segment product portfolio: 45+ Active Pharmaceutical Ingredients (APIs) spanning analgesics, NSAIDs, antibiotics, anti-malarials, anti-diabetics, corticosteroids, and other therapeutic categories; finished dosage formulations in tablet, capsule, suspension, injection, and sachet forms under branded labels such as ASKPROL, CINGOL, PROMY, FOLAMIN, FLOXCIP, LENON, Cefask, and Triaxonecit; and a nutraceuticals line including vitamins, minerals, herbal supplements, and combination products under sub-brands like Vitamina-Z, Vitolux, Cidoxon, Redcal, Selvit, and CitIvy Syrup. Underpinning the portfolio is a claimed 25,000 sq/ft state-of-the-art R&D laboratory focused on nutraceutical molecule research, local reference standard development, and novel drug delivery systems.

The business model centers on direct B2B sales of APIs and formulations, complemented by a growing B2C nutraceuticals consumer line, with revenue generated through hardware/product sales rather than subscription or platform models. Distribution relies on direct export relationships (Uzbekistan for Ibuprofen, USA for Nutraceuticals, Dubai for Paracetamol and Amoxicillin) and international joint ventures targeting MENA and Southeast Asian markets. Pricing is not publicly disclosed. Go-to-market combines a sales-led motion with content marketing, LinkedIn presence, and conference participation (Health Expo Iraq, ISPE Singapore 2025). The company recently received SECP approval for a wholly owned REIT management subsidiary (CITI REIT Management Company Limited) marking diversification into real estate, and has initiated strategic partnerships in biotech and with the Gates Foundation to broaden its institutional footprint.

Short descriptiontext

Citi Pharma Limited is a Lahore-based, Pakistan-listed pharmaceutical manufacturer producing 45+ APIs, finished formulations, and nutraceuticals for domestic and export markets across Uzbekistan, USA, UAE, Iraq, and Indonesia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLahore, Pakistan
HQ citystring
Lahore
HQ countrystring
Pakistan
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
active pharmaceutical ingredients, pharmaceutical formulations, nutraceutical supplements, generic drug manufacturing, pharmaceutical research and development
Industry1 code
PRIMARYCRADAGAC
Multivitamins & Daily Packs
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Products
TypeHardware Sales
Description

Citi Pharma generates revenue through the manufacture and sale of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and nutraceutical products. The company exports to Uzbekistan (Ibuprofen), USA (Nutraceuticals), and Dubai (Paracetamol and Amoxicillin).

citipharma.com.pk
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Citi Natural
Description

A product sub-brand mentioned under the products section.

citipharma.com.pk
Core offering1 text field

Citi Pharma manufactures and sells Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations (capsules, tablets, syrup drops, ointments, sachets), and nutraceutical products under its Citi Natural sub-brand. The company runs a 25,000 sq/ft state-of-the-art R&D laboratory that supports drug delivery research and reference-standard development. It supplies both domestic Pakistani markets and export markets in Uzbekistan, the USA, the UAE (Dubai), Iraq, and Indonesia.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Citi Pharma is a Pakistani pharmaceutical company offering a three-segment product portfolio: (1) Active Pharmaceutical Ingredients (API) encompassing 45+ molecules across analgesics, NSAIDs, antibiotics (quinolones, penicillins, cephalosporins, macrolides), anti-malarials, anti-diabetics, and other therapeutic categories; (2) Finished Dosage Formulations including branded medications like ASKPROL (analgesics), CINGOL (respiratory), Cefask/Triaxonecit (antibiotics), and others in tablet, capsule, suspension, and injection forms; and (3) Nutraceuticals including vitamins, minerals, herbal supplements in tablet, capsule, syrup, and sachet formats. The company operates a 25,000 sq/ft R&D laboratory for new molecule research and drug delivery innovation.

Product and service3 records
1Active Pharmaceutical Ingredients (APIs)
CategoryActive Pharmaceutical Ingredients
Description

Manufactured active pharmaceutical ingredients supplied primarily to other pharmaceutical manufacturers as raw input materials for their own formulations. APIs are produced at the company's facilities in Pakistan and supported by in-house reference-standard development capability.

2Pharmaceutical Formulations
CategoryFinished Formulations
Description

Finished pharmaceutical formulations in multiple dosage forms including capsules, tablets, syrups, drops, ointments, and sachets. Branded product families include ASKPROL (analgesic line with ASKPROL EXTRA, ASKPROL-M MIGRAINE, ASKPROL TABLET, ASKPROL Suspension variants), CINGOL (respiratory), PROMY (Omeprazole), FOLAMIN (nutritional), FLOXCIP, LENON, Cefask, and Triaxonecit (antibiotics). Sold domestically in Pakistan and exported to international markets including Uzbekistan, USA, UAE (Dubai), Iraq, and Indonesia.

3Citi Natural Nutraceuticals
CategoryNutraceuticals
Description

Nutraceutical / dietary supplement product line marketed under the Citi Natural sub-brand. Sub-products include Vitamina-Z Tablet, Vitolux Tablet, Cidoxon Tablet, Redcal Tablet, Selvit Capsule, and CitIvy Syrup. Targeted at consumers seeking vitamins, minerals, and nutritional support products sold through retail and pharmacy channels.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-04
Description

Citi Pharma hosted a productive meeting with the Gates Foundation team to explore opportunities for collaboration on innovative healthcare solutions. The company aims to drive meaningful impact in global health through this potential partnership.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

MD Dr Zamir Ul Hussan connected with global pharma leaders at ISPE Singapore 2025, exchanging insights on innovation, quality, and the future of healthcare.

3Strategic Biotech Partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic partnership bringing advanced biotech technologies, promoting local research, and creating high-value jobs. The partnership strengthens local manufacturing, reduces import reliance, and boosts export potential.

citipharma.com.pk
4International Joint Ventures Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International joint ventures for API expansion, establishment of pharmaceutical manufacturing facilities, and expansion into MENA region. Includes collaboration with Ambassador of Indonesia at Citi Pharma Plant.

citipharma.com.pk
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1The Searle Company
TypeDirect peer
Description

Pakistani publicly listed pharma manufacturer with diversified branded generics, APIs, and nutraceutical/nutrition portfolio, operating internationally with similar product segmentation to Citi Pharma.

TypeDirect peer
Description

Karachi-based pharmaceutical company manufacturing branded generics, APIs, and over-the-counter products with strong domestic distribution and select export reach, closely matching Citi Pharma's domestic-plus-export model.

TypeDirect peer
Description

Listed Pakistani pharma company with branded generics, API manufacturing, and a partnership with Gilead for hepatitis C treatment; comparable as a manufacturer with API capabilities and international collaborations.

TypeDirect peer
Description

Pakistan's leading sterile injectable manufacturer with API and formulation capabilities, including beta-lactam antibiotics — directly overlapping Citi Pharma's Triaxonecit (Ceftriaxone) and cephalosporin product lines.

TypeDirect peer
Description

Pakistan's largest pharmaceutical manufacturer producing APIs, formulations, and branded generics across antibiotics, cardiovascular, and nutraceuticals; directly comparable as a domestic pharma with manufacturing, exports, and 1,000+ employee scale.

TypeBroad incumbent
Description

Large Indian generic and API manufacturer with extensive global presence across antibiotics, anti-retrovirals, and nutraceuticals; sets the competitive benchmark for cost-efficient API-plus-formulation players seeking regulated market exports.

TypeDirect peer
Description

Pakistan-based pharma manufacturer producing APIs, finished formulations, and specialty products across antibiotics, anti-malarials, and cardiovascular; comparable in API-plus-formulation vertical integration and headcount scale.

TypeDirect peer
Description

Pakistan-based pharmaceutical manufacturer producing branded generics and OTC products across cardiovascular, gastrointestinal, and nutraceutical segments, similar in size and therapeutic breadth to Citi Pharma.

TypeBroad incumbent
Description

India-headquartered global pharmaceutical major with APIs, formulations, and nutraceuticals across 80+ countries; serves as a comparable incumbent in the broader generics and API space where Citi Pharma competes for export markets.

TypeDirect peer
Description

Karachi-headquartered pharma manufacturer with branded generics, specialty products, and exports; comparable in therapeutic portfolio and regional export orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Citi Pharma

Pharmaceutical Manufacturingcitipharma.com.pk

Citi Pharma Limited is a Lahore-based, Pakistan-listed pharmaceutical manufacturer producing 45+ APIs, finished formulations, and nutraceuticals for domestic and export markets across Uzbekistan, USA, UAE, Iraq, and Indonesia.

What Citi Pharma does

Citi Pharma Limited is a Pakistan-based pharmaceutical company founded in 1992 and headquartered in Lahore, operating as a publicly listed entity on the Pakistan Stock Exchange with offices in Lahore and Karachi and a manufacturing facility in Bhai Pheru, District Kasur. The company operates a three-segment product portfolio: 45+ Active Pharmaceutical Ingredients (APIs) spanning analgesics, NSAIDs, antibiotics, anti-malarials, anti-diabetics, corticosteroids, and other therapeutic categories; finished dosage formulations in tablet, capsule, suspension, injection, and sachet forms under branded labels such as ASKPROL, CINGOL, PROMY, FOLAMIN, FLOXCIP, LENON, Cefask, and Triaxonecit; and a nutraceuticals line including vitamins, minerals, herbal supplements, and combination products under sub-brands like Vitamina-Z, Vitolux, Cidoxon, Redcal, Selvit, and CitIvy Syrup. Underpinning the portfolio is a claimed 25,000 sq/ft state-of-the-art R&D laboratory focused on nutraceutical molecule research, local reference standard development, and novel drug delivery systems.

The business model centers on direct B2B sales of APIs and formulations, complemented by a growing B2C nutraceuticals consumer line, with revenue generated through hardware/product sales rather than subscription or platform models. Distribution relies on direct export relationships (Uzbekistan for Ibuprofen, USA for Nutraceuticals, Dubai for Paracetamol and Amoxicillin) and international joint ventures targeting MENA and Southeast Asian markets. Pricing is not publicly disclosed. Go-to-market combines a sales-led motion with content marketing, LinkedIn presence, and conference participation (Health Expo Iraq, ISPE Singapore 2025). The company recently received SECP approval for a wholly owned REIT management subsidiary (CITI REIT Management Company Limited) marking diversification into real estate, and has initiated strategic partnerships in biotech and with the Gates Foundation to broaden its institutional footprint.

Citi Pharma firmographics

Firmographics
Name
Citi Pharma
Legal name
Citi Pharma Limited
Website
https://citipharma.com.pk
Company type
Public
Founded year
1993
Operating status
Operating
Headcount range
251–500 employees
Short description
Citi Pharma Limited is a Lahore-based, Pakistan-listed pharmaceutical manufacturer producing 45+ APIs, finished formulations, and nutraceuticals for domestic and export markets across Uzbekistan, USA, UAE, Iraq, and Indonesia.
Ownership category
akta.pro rank

Citi Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRADAGAC
Multivitamins & Daily Packs

Keywords

  • Active pharmaceutical ingredients
  • Pharmaceutical formulations
  • Nutraceutical supplements
  • Generic drug manufacturing
  • Pharmaceutical research and development

Where Citi Pharma is headquartered

Location

Headquarters

HQ city
Lahore
HQ country
Pakistan
HQ region
Asia

Offices3 records

Markets served

Citi Pharma business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Products: Citi Pharma generates revenue through the manufacture and sale of Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, and nutraceutical products. The company exports to Uzbekistan (Ibuprofen), USA (Nutraceuticals), and Dubai (Paracetamol and Amoxicillin).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Citi Pharma product offering

Product offering

Core offering

Citi Pharma manufactures and sells Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations (capsules, tablets, syrup drops, ointments, sachets), and nutraceutical products under its Citi Natural sub-brand. The company runs a 25,000 sq/ft state-of-the-art R&D laboratory that supports drug delivery research and reference-standard development. It supplies both domestic Pakistani markets and export markets in Uzbekistan, the USA, the UAE (Dubai), Iraq, and Indonesia.

Product overview

Citi Pharma is a Pakistani pharmaceutical company offering a three-segment product portfolio: (1) Active Pharmaceutical Ingredients (API) encompassing 45+ molecules across analgesics, NSAIDs, antibiotics (quinolones, penicillins, cephalosporins, macrolides), anti-malarials, anti-diabetics, and other therapeutic categories; (2) Finished Dosage Formulations including branded medications like ASKPROL (analgesics), CINGOL (respiratory), Cefask/Triaxonecit (antibiotics), and others in tablet, capsule, suspension, and injection forms; and (3) Nutraceuticals including vitamins, minerals, herbal supplements in tablet, capsule, syrup, and sachet formats. The company operates a 25,000 sq/ft R&D laboratory for new molecule research and drug delivery innovation.

Differentiator

Problem solved

Functional benefit

Brands

  • Citi Natural: A product sub-brand mentioned under the products section.

Products and services

  • Active Pharmaceutical Ingredients (APIs) Manufactured active pharmaceutical ingredients supplied primarily to other pharmaceutical manufacturers as raw input materials for their own formulations. APIs are produced at the company's facilities in Pakistan and supported by in-house reference-standard development capability.
  • Pharmaceutical Formulations Finished pharmaceutical formulations in multiple dosage forms including capsules, tablets, syrups, drops, ointments, and sachets. Branded product families include ASKPROL (analgesic line with ASKPROL EXTRA, ASKPROL-M MIGRAINE, ASKPROL TABLET, ASKPROL Suspension variants), CINGOL (respiratory), PROMY (Omeprazole), FOLAMIN (nutritional), FLOXCIP, LENON, Cefask, and Triaxonecit (antibiotics). Sold domestically in Pakistan and exported to international markets including Uzbekistan, USA, UAE (Dubai), Iraq, and Indonesia.
  • Citi Natural Nutraceuticals Nutraceutical / dietary supplement product line marketed under the Citi Natural sub-brand. Sub-products include Vitamina-Z Tablet, Vitolux Tablet, Cidoxon Tablet, Redcal Tablet, Selvit Capsule, and CitIvy Syrup. Targeted at consumers seeking vitamins, minerals, and nutritional support products sold through retail and pharmacy channels.

Companies that use Citi Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Citi Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Citi Pharma partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Gates FoundationcoreStrategic or Co-development Partner · 4 August 2025Citi Pharma hosted a productive meeting with the Gates Foundation team to explore opportunities for collaboration on innovative healthcare solutions. The company aims to drive meaningful impact in global health through this potential partnership.
  • ISPE (International Society for Pharmaceutical Engineering)minorStrategic or Co-development Partner · 1 January 2025MD Dr Zamir Ul Hussan connected with global pharma leaders at ISPE Singapore 2025, exchanging insights on innovation, quality, and the future of healthcare.
  • Strategic Biotech PartnercoreStrategic or Co-development Partner · 1 January 2024Strategic partnership bringing advanced biotech technologies, promoting local research, and creating high-value jobs. The partnership strengthens local manufacturing, reduces import reliance, and boosts export potential.
  • International Joint Ventures PartnerscoreStrategic or Co-development PartnerInternational joint ventures for API expansion, establishment of pharmaceutical manufacturing facilities, and expansion into MENA region. Includes collaboration with Ambassador of Indonesia at Citi Pharma Plant.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Citi Pharma competitors and assessment

Company assessment

Direct peers

  • The Searle Company: Pakistani publicly listed pharma manufacturer with diversified branded generics, APIs, and nutraceutical/nutrition portfolio, operating internationally with similar product segmentation to Citi Pharma.
  • Hilton Pharma: Karachi-based pharmaceutical company manufacturing branded generics, APIs, and over-the-counter products with strong domestic distribution and select export reach, closely matching Citi Pharma's domestic-plus-export model.
  • Ferozsons Laboratories: Listed Pakistani pharma company with branded generics, API manufacturing, and a partnership with Gilead for hepatitis C treatment; comparable as a manufacturer with API capabilities and international collaborations.
  • Barrett Hodgson Pakistan: Pakistan's leading sterile injectable manufacturer with API and formulation capabilities, including beta-lactam antibiotics — directly overlapping Citi Pharma's Triaxonecit (Ceftriaxone) and cephalosporin product lines.
  • Getz Pharma: Pakistan's largest pharmaceutical manufacturer producing APIs, formulations, and branded generics across antibiotics, cardiovascular, and nutraceuticals; directly comparable as a domestic pharma with manufacturing, exports, and 1,000+ employee scale.
  • Highnoon Laboratories: Pakistan-based pharma manufacturer producing APIs, finished formulations, and specialty products across antibiotics, anti-malarials, and cardiovascular; comparable in API-plus-formulation vertical integration and headcount scale.
  • AGP Limited: Pakistan-based pharmaceutical manufacturer producing branded generics and OTC products across cardiovascular, gastrointestinal, and nutraceutical segments, similar in size and therapeutic breadth to Citi Pharma.
  • Sami Pharmaceuticals: Karachi-headquartered pharma manufacturer with branded generics, specialty products, and exports; comparable in therapeutic portfolio and regional export orientation.

Broad incumbents

  • Aurobindo Pharma: Large Indian generic and API manufacturer with extensive global presence across antibiotics, anti-retrovirals, and nutraceuticals; sets the competitive benchmark for cost-efficient API-plus-formulation players seeking regulated market exports.
  • Cipla: India-headquartered global pharmaceutical major with APIs, formulations, and nutraceuticals across 80+ countries; serves as a comparable incumbent in the broader generics and API space where Citi Pharma competes for export markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Citi Pharma social profiles

Digital presence

Citi Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Citi Pharma leadership team

Management profile

Number of profiles

Profiles3 records

Citi Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Citi Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Citi Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Citi Pharma

What does Citi Pharma do?

Citi Pharma manufactures and sells Active Pharmaceutical Ingredients (APIs), finished pharmaceutical formulations (capsules, tablets, syrup drops, ointments, sachets), and nutraceutical products under its Citi Natural sub-brand. The company runs a 25,000 sq/ft state-of-the-art R&D laboratory that supports drug delivery research and reference-standard development. It supplies both domestic Pakistani markets and export markets in Uzbekistan, the USA, the UAE (Dubai), Iraq, and Indonesia.

Is Citi Pharma a public or private company?

Citi Pharma is a public company. It is classified as public and is currently operating.

When was Citi Pharma founded?

Citi Pharma was founded in 1993. It employs 251 to 500 people.

Where is Citi Pharma based?

Citi Pharma is headquartered in Lahore, Pakistan, in the Asia region.

How does Citi Pharma make money?

One revenue line is on record: pharmaceutical Products.

Who are Citi Pharma's main competitors?

Direct peers on record are The Searle Company, Hilton Pharma, Ferozsons Laboratories, Barrett Hodgson Pakistan, Getz Pharma, Highnoon Laboratories, AGP Limited and Sami Pharmaceuticals. Broad incumbents are Aurobindo Pharma and Cipla.

Does Citi Pharma have an API?

No public API is recorded for Citi Pharma.

What industry is Citi Pharma in?

Citi Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is CRADAGAC, Multivitamins & Daily Packs. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business RecorderCiti Pharma Limited: performance and outlookCiti Pharma Limited, listed on Pakistan Stock Exchange in 2021, reported net sales of Rs.13,153.52 million in FY25, up 6 percent, with net profit of Rs.892.039 million and a 7 percent year-on-year rise. GP margin reached 15.34 percent in 2025, while debt-to-equity climbed to 70 percent. The company plans to acquire Pakheim International Pharmaceuticals for 100 percent on May 6, 2026.Business RecorderCiti Pharma Limited: performance and outlookCiti Pharma Limited reported steady financial growth from 2021 to 2025, with net sales rising from Rs.5795.40 million in 2021 to Rs.13,153.52 million in 2025. Margins peaked in 2025 at 15.34% gross and 6.78% net, and the company plans to acquire Pakheim International Pharmaceuticals in May 2026.PropakistaniCiti Pharma to Acquire Lahore-Based Medicine ManufacturerCiti Pharma announced a plan to acquire 100% of Pakheim International Pharmaceuticals, a Lahore-based manufacturer, on May 6, 2026. Pakheim generates about Rs. 500 million annually, and the deal is financed via internal cash and banking facilities, with payment extending to December 31, 2026. The company targets Rs. 5 billion in revenue over five years.Mettis Global LinkCPHL targets full takeover of Pakheim International PharmaceuticalsCiti Pharma Ltd. approved a proposal to acquire 100% of Pakheim International Pharmaceuticals, including its assets, licenses, and operations. The deal aims to strengthen manufacturing capacity and expand product portfolio, subject to regulatory approvals and due diligence. Financing will come from internal cash and banking facilities.Business RecorderPakistan’s Citi Pharma targets real estate growth with new subsidiaryCiti Pharma Limited, a Pakistani pharmaceutical company, has received Securities and Exchange Commission of Pakistan (SECP) approval to establish a wholly owned REIT management subsidiary named CITI REIT Management Company Limited, marking its strategic entry into the real estate sector. The company plans three development projects in Lahore and near Islamabad International Airport, contributing land valued at approximately Rs7 billion, with completion targeted by the end of Q1 FY2026-27. The REIT structure is expected to generate ongoing dividend returns for Citi Pharma while creating value for shareholders through transparent and regulated real estate investments.Profit by Pakistan TodayCiti Pharma dips its toes into veterinary medicineCiti Pharma's subsidiary Citi Veterinary Limited began operations on September 12, 2025, launching 32 veterinary products including vaccines. The company projects PKR 1.5 billion turnover for fiscal 2025-26 and aims to reach PKR 10 billion within three years.Profit by Pakistan TodayCiti Pharma’s veterinary subsidiary begins operations, launching 32 products initiallyCiti Pharma's subsidiary Citi Veterinary Limited began trading operations, launching 32 veterinary products with LCs for 8. It expects PKR 1.5 billion turnover in FY2025-26 and plans a PKR 10 billion target within three years. The company also plans Pakistan's first dedicated veterinary API plant in FY2026-27.